Log in to save to my catalogue

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8757570

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. Adverse effects in the remdesivir group were similar to those in the placebo group.

Alternative Titles

Full title

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8757570

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8757570

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2116846

How to access this item